DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The "Global Atherothrombosis Epidemiology and Patient Flow Analysis - 2018" report has been added to ResearchAndMarkets.com's offering.

The research provides insights into Atherothrombosis epidemiology, Atherothrombosis diagnosed patients, and Atherothrombosis treatment rate for US, Japan, and EU5 countries. The research measures key indicators including prevalence of Atherothrombosis derived from epidemiological analysis, patients diagnosed with Atherothrombosis, and patients treated with a drug therapy.

The research study helps executives estimate Atherothrombosis market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The research provides estimates and forecasts of Atherothrombosis prevalence, Atherothrombosis diagnosis rate, and Atherothrombosis treatment rate for the period 2017-2026. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan.

Key Features

Atherothrombosis Patient Flow Atherothrombosis Prevalence Atherothrombosis Diagnosed Patients Atherothrombosis Treated Patients

Key Topics Covered

1. Atherothrombosis: Disease Definition

2. Global Atherothrombosis Patient Flow

2A. Global Atherothrombosis Prevalence

2B. Global Atherothrombosis Diagnosed Patients

2C. Global Atherothrombosis Treated Patients

3. Atherothrombosis Patient Flow in the US

3A. Atherothrombosis Prevalence in the US

3B. Atherothrombosis Diagnosed Patients in the US

3C. Atherothrombosis Treated Patients in the US

4. Atherothrombosis Patient Flow in Europe

4A. Atherothrombosis Prevalence in Europe

4B. Atherothrombosis Diagnosed Patients in Europe

4C. Atherothrombosis Treated Patients in Europe

5. Atherothrombosis Patient Flow in Germany

5A. Atherothrombosis Prevalence in Germany

5B. Atherothrombosis Diagnosed Patients in Germany

5C. Atherothrombosis Treated Patients in Germany

6. Atherothrombosis Patient Flow in France

6A. Atherothrombosis Prevalence in France

6B. Atherothrombosis Diagnosed Patients in France

6C. Atherothrombosis Treated Patients in France

7. Atherothrombosis Patient Flow in Spain

7A. Atherothrombosis Prevalence in Spain

7B. Atherothrombosis Diagnosed Patients in Spain

7C. Atherothrombosis Treated Patients in Spain

8. Atherothrombosis Patient Flow in Italy

8A. Atherothrombosis Prevalence in Italy

8B. Atherothrombosis Diagnosed Patients in Italy

8C. Atherothrombosis Treated Patients in Italy

9. Atherothrombosis Patient Flow in UK

9A. Atherothrombosis Prevalence in UK

9B. Atherothrombosis Diagnosed Patients in UK

9C. Atherothrombosis Treated Patients in UK

10. Atherothrombosis Patient Flow in Japan

10A. Atherothrombosis Prevalence in Japan

10B. Atherothrombosis Diagnosed Patients in Japan

10C. Atherothrombosis Treated Patients in Japan

11. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/research/vlfkkb/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180611006226/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/11/2018 05:02 PM/DISC: 06/11/2018 05:01 PM

http://www.businesswire.com/news/home/20180611006226/en